Abbott Laboratories (ABT) Earnings Date & Reports

Key Takeaways

• Abbott reported adjusted earnings per share (EPS) of $1.42, up 9.2% from $1.30 a year ago and slightly below the consensus estimate of $1.43.
• Revenue rose 14.5% on a reported basis to $13.01 billion, with comparable (organic) sales growth of 7.0%, led by double-digit gains in Electrophysiology and Rhythm Management.
• Abbott tightened its full-year 2026 adjusted EPS guidance to $5.50–$5.55 but lowered its comparable sales growth outlook to approximately 6.0%, down from 6.5%–7.5%.
• The company announced plans to spin off its Nutrition business into a separate, publicly traded company by the end of 2027.
• Shares fell roughly 3.6% in pre-market trading, with the lowered sales outlook and restructuring announcement weighing on sentiment.

Earnings Context and Why It Matters

Abbott Laboratories is a diversified healthcare company spanning medical devices, diagnostics, established pharmaceuticals, and nutrition. Its third-quarter 2026 results matter because they show whether management can sustain an acceleration in both top- and bottom-line growth after a comparatively slower first half. The quarter was also shaped by two major developments: the March 2026 acquisition of Exact Sciences, which transformed the Diagnostics segment, and the newly announced plan to separate the Nutrition business. Investors are closely watching whether core franchises such as diabetes care and electrophysiology can keep growing while the company reshapes its portfolio and margins.

Reported Results

For the third quarter ended September 30, 2026, Abbott reported net sales of $13.01 billion, up 14.5% on a reported basis and 7.0% on a comparable basis from $11.37 billion a year earlier. Adjusted diluted EPS came in at $1.42, compared with $1.30 in the prior-year period. On a generally accepted accounting principles (GAAP) basis, diluted EPS from continuing operations was $0.53, down from $0.94 a year ago, reflecting the impact of specified items.

Across segments, Medical Devices sales rose 6.9% on a reported basis to $5.83 billion (7.8% comparable), with Electrophysiology up 15.5% and Rhythm Management up 10%. Diagnostics surged 46.7% on a reported basis to $3.31 billion, boosted by Exact Sciences, while comparable growth was 6.4%. Established Pharmaceuticals grew 6.8% to $1.61 billion (8.4% comparable), and Nutrition rose 5.1% to $2.26 billion (4.9% comparable), led by an 8.7% increase in Pediatric Nutrition.

AI Screener

For investors tracking earnings momentum and sector trends, Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to see how it can support your own research process.

Market Reaction and Investor Sentiment

Shares of Abbott slipped about 3.6% in pre-market trading after the release, as investors weighed a mixed quarter against the strategic news. The slight EPS miss versus consensus and the reduction in full-year comparable sales growth guidance were the main drags on sentiment, even though revenue edged past estimates and profitability improved. The expanded adjusted gross margin of 57.2%, up roughly 143 basis points (bps) year over year, was a bright spot. The announcement of the Nutrition spin-off added a layer of uncertainty, with investors assessing both the long-term benefits of a more focused portfolio and the near-term execution risks.

Forward Outlook and Key Factors to Monitor

Abbott tightened its full-year 2026 adjusted EPS guidance to a range of $5.50 to $5.55, reaffirming the midpoint of its previous range. However, management now projects comparable sales growth of approximately 6.0% for the year, down from a prior range of 6.5% to 7.5%. For the fourth quarter, Abbott guided to adjusted EPS of $1.62 to $1.67.

Investors should monitor several factors going forward. First, the planned separation of the Nutrition business — which generates roughly $8.5 billion in annual revenue through brands such as Similac, Ensure, and Pedialyte — will reshape Abbott's growth profile and is expected to improve overall sales growth and operating margins over time. Second, the pace of adoption of new devices, including the Volt pulsed-field ablation (PFA) catheter in Electrophysiology and the newly approved Libre Duo glucose-ketone sensor in Diabetes Care, will be key demand signals.

Finally, watch margin trends and cost discipline, as well as the continued integration of Exact Sciences within Diagnostics. Foreign exchange is also expected to have a roughly 1% negative impact on fourth-quarter sales. These elements will help determine whether Abbott's growth acceleration can be sustained into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations